IPROZILAMINE, a member of 4-piperazinopyrimidines, has powerful antiemetic activity. It also exhibits a relaxant effect on smooth muscle fiber.

Ipatasertib, an investigational Akt inhibitor, is currently in clinical development based on its potential to specifically target Akt in tumors with activated Akt signaling. Preclinical data have shown that ipatasertib selectively decreased cell viability and increased apoptosis in tumor cell lines characterized by activated Akt. Ipatasertib is advancing in clinical development including three Phase 2 trials in patients with breast cancer, gastric cancer and prostate cancer. The most commonly reported adverse events associated with Ipatasertib were Grade 1-2 diarrhea, nausea, fatigue, vomiting, decreased appetite and rash.

Ioxabrolic Acid is triiodobenzoic acid derivative and iodine-containing contrast media

Iomorinic Acid is triiodobenzamide derivative patented by Lentia G.m.b.H. as a radiographic contrast medium for liver imaging.

Indorenate (TR3369, INDO) is a serotonin-like compound with high affinity for 5- HT1A receptors and a lower affinity for 5-HT1C and 5-HT1B receptors. Indorenate possesses antihypertensive and anxiolytic activity in animal behaviour tests. Similar to other serotonin receptor agonists, Indorenate also has anorectic activity; this effect was blocked by the administration of the 5-HT2A/2C receptor antagonists cinanserin, cyproheptadine, metergoline and methysergide. A unpublished clinical trial confirmed its antihypertensive activity in men.

Imisopasem Manganese is a manganese-based non-peptidyl mimetic of the human mitochondrial manganese superoxide dismutase (MnSOD), with potential antioxidant and radioprotective activities. Metaphore Pharmaceuticals Inc. is developing Imisopasem Manganese for the potential treatment of pain, dermatological disease and inflammation. Upon administration, imisopasem manganese mimics the activity of MnSOD and scavenges reactive oxygen species (ROS), such as superoxide anion, which prevents oxygen free radical damage to macromolecules such as DNA. This reduces ROS-mediated lipid peroxidation, prevents apoptosis and protects against oxygen free radical-induced toxicity in normal tissues.

Luxabendazole is a benzimidazole carbamate antihelmintic agent. In animal studies, it was effective against adult and immature stages of the major gastrointestinal nematodes, trematodes and cestodes.

Enloplatin (CL 287110) is a platinum complex with antineoplastic properties. It is more water soluble than cisplatin. Enloplatin was developing by Wyeth-Lederle for the treatment of patients with ovarian cancer and leukemia.

Fenamifuril is an antiinflammatory and antirheumatic agent.